Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
AssigneeStcube, Inc.
InventorsStephen Sunghan Yoo, Ezra Myung Chul Chung, Yong-Sik Bong, Yong-Soo Kim, Andrew H. Park
Life of this patent
Estimating the term…
Abstract
Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
Claims26
1-111. (canceled)
A method of detecting an expression level of BTN1A1 comprising contacting a sample from a subject with an anti-BTN1A1 antibody or antigen-binding fragment thereof, and detecting the presence of the anti-BTN1A1 antibody or antigen-binding fragment thereof bound to the sample, wherein the antibody or antigen-binding fragment thereof immunospecifically binds to BTN1A1, wherein the expression level of BTN1A1 in the sample is compared to a reference level.
The method of 116, wherein the anti-BTN1A1 antibody or the antigen-binding fragment thereof comprises
- (a) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:3;
- (b) a VH comprising an amino acid sequence of SEQ ID NO:3;
- (c) a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:5;
- (d) a VL comprising an amino acid sequence of SEQ ID NO:5;
- or
- (e) a VH comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:3;
- and a VL comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO:5.
Dependencies are inferred from the claim text.